Biotech entity
Insilico Medicine is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Coverage clusters in pharma, which accounts for 2 of those 3, with the remainder spread across 1 other category. Each story carries 2.7 original sources on average, compared with 3.8 for the broader beat in this window.
Last mentioned: Jun 23, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Insilico Medicine is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Coverage clusters in pharma, which accounts for 2 of those 3, with the remainder spread across 1 other category. Each story carries 2.7 original sources on average, compared with 3.8 for the broader beat in this window. The 132-day window averages about 0.2 stories each week. Their average consequence score of 7 runs above the beat's 6.3 for that window. This profile follows 3 Biotech stories mentioning Pharma.AI across the period from March 6, 2026 to July 15, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 395 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Pharma.AI. Shared-story counts are live from our verified record — not editorial picks.
Phase I Initiation
First human subject enrolled and dosed in the Phase I clinical trial.
Out-Licensing Deal
TaiGen Biopharmaceuticals acquires rights for clinical development and commercialization.
Candidate Discovery
Insilico Medicine identifies ISM4808 using generative AI models.
The proposed alliance between AI powerhouse Insilico Medicine and CDMO Bora Pharmaceuticals could create a seamless pipeline from generative chemistry to commercial manufacturing. With a headline potential of over $2.5 billion, the deal targets multiple therapeutic programs and directly addresses the translational gap that often stalls promising drug candidates.
Source: prnewswire.com · prnewswire.com
In the largest Asia‑Pacific licensing deal for Insilico Medicine, the AI‑first biotech secured up to $2.5 billion in milestones plus royalties from South Korea's SK Biopharmaceuticals, a CNS powerhouse, to co‑develop next‑generation neuroimmune therapies. The heavily back‑ended structure reflects industry‑standard risk‑sharing, with Insilico taking $18M up front and SK steering commercialization, underscoring a growing appetite for AI‑discovered assets in big pharma pipelines.
Insilico Medicine and TaiGen Biopharmaceuticals have achieved a major clinical milestone with the first human dosing of ISM4808, an AI-discovered small molecule for Chronic Kidney Disease (CKD) anemia. This Phase I trial marks a critical validation point for Insilico’s Pharma.AI platform and triggers a milestone payment from TaiGen.
Pharma.AI is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
